Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection could beat tough eye infections that drops Can't handle

NCT ID NCT07394257

Disease control Sponsor: Minia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 11, 2026 · Updated 3 times

Summary

This study tests whether injecting the antibiotic moxifloxacin directly into the cornea can help treat bacterial eye infections that don't improve with standard antibiotic drops. About 60 adults with stubborn corneal infections will receive either the injection plus drops or drops alone. The goal is to see if the injection speeds up healing and improves vision.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
moxifloxacin
What this could lead to
If it works, this could offer a better way to treat deep corneal infections that don't heal with standard antibiotic eye drops, potentially saving eyesight.
What could go wrong
This is a small, early-stage trial with only 60 participants, so results may not apply to everyone. The injection itself carries risks like corneal damage or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Age ≥ 18 years * Clinical diagnosis of bacterial keratitis confirmed by corneal scraping and microbiology * Recalcitrant keratitis defined as no significant clinical improvement after 48-72 hours of intensive topical antibiotic therapy * Ability to provide written informed consent Exclusion Criteria * Fungal, viral, or acanthamoeba keratitis * Corneal perforation or impending perforation * Known hypersensitivity to fluoroquinolones * Pregnancy or lactation * Immunocompromised state or current systemic immunosuppressive therapy * Previous intrastromal or intracameral antibiotic injection for the same episode

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacterial keratitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

corneal infection corneal ulcer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bacterial keratitis Corneal ulcer Recalcitrant infectious keratitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mahmoud Ramadan Amer

    RECRUITING

    Minya, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.